Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Auteurs

Leboulleux S, Kapiteijn E, Litière S, Schöffski P, Godbert Y, Rodien P, Jarzab B, Salvatore D, Zanetta S, Capdevila J, Bastholt L, De La Fouchardiere C, Lalami Y, Bardet S, Cornélis F, Dedecjus M, Links T, Sents W, Schlumberger M, Locati DL, Newbold K

  • Date de publication

    Januari 2024

  • Type

    Article

  • Tijdschrift

    Front Endocrinol (Lausanne)

  • Naam van de onderzoeker

    LALAMI YASSINE

  • Hôpital

    Institut Jules Bordet

  • Dienst

    Médecine Oncologique

  • PMID

    39015176

  • DOI

    10.3389/fendo.2024.1403687